Pharmacokinetics of reboxetine in volunteers with hepatic impairment

Clinical Drug Investigation

Volumn 19, Issue 6, 2000, Pages 473-477

  Tran, A ^a   Laneury, J P ^b   Duchene P ^b   Jannuzzo, M G ^c   Fleishaker, J C ^c   Houin, G ^d   Rampal, P ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b ADME Bioanalyses SA   (France)

^c PFIZER INC   (United States)

^d TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; REBOXETINE;

ADULT; AGED; ALCOHOL LIVER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER DYSFUNCTION; MALE; PRIORITY JOURNAL;

EID: 0034047644     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200019060-00010     Document Type: Article

References (13)

1. 1. Montgomery SA. Reboxetine: additional benefits to the depressed patient. J Psychopharmacol 1997; 11 (4 Suppl.): S9-S15
2. 2. Mucci M. Reboxetine: a review of antidepressant tolerability. J Psychopharmacol 1997; 11 (4 Suppl.): S33-S37
3. 3. Edwards DMF, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxetine in healthy volunteers: single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 1995; 16:443-60
4. 4. Pellizzoni C, Strolin Benedetti M, Poggesi I, et al. Pharmacokinetics of reboxetine in healthy volunteers: relative bioavailability and food effect. Pharmacol Res 1995; 31 Suppl.: 41
5. 5. Dostert P, Benedetti MS, Poggesi I. Review of pharmacokinetics and metabolism of reboxetine, a selective nor-adrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997;7:S23-S35
6. 6. Sherlock S. Drugs and the liver. In: Diseases of the liver and biliary system, 8th edition. Oxford: Blackwell Scientific Publications, 1989: 372-109
7. 7. Child CJ. The liver and portal hypertension. Philadelphia: Saunders, 1964
8. 8. Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9
9. 9. Jannuzzo MG, Ryde M, Karlmark B, et al. Pharmacokinetics of reboxetine in healthy volunteers of different ages [abstract P-2-77]. Eur Neuropsychopharmacol 1995; 5 (3): 300
10. 10. Tsujimoto G, Hashimoto K, Hoffman BB. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age. Pt I. Int J Clin Pharmacol Ther Toxicol 1989; 27: 13-26
11. 11. Pellizzoni C, Poggesi I, Jørgensen NP, et al. Pharmacokinetics of reboxetine in healthy volunteers: single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Dispos 1996; 17: 623-33
12. 12. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481-508
13. 13. Demolis JL, Angebaud P, Grangé JD, et al. Comparison of pharmacokinetics of orally administered sertraline in patients with stable chronic hepatic insufficiency and in healthy subjects. Fundam Clin Pharmacol 1993; 7: 355